Mirus Bio receives ISO 13485:2016 certification, underscoring the quality of processes used to support GMP product portfolio. Read more

mirus bio logo
Search
Close this search box.

TransIT-QR Delivery Solution – 40 Injections

A nontoxic, “Quick Recovery” in vivo delivery solution that delivers DNA or siRNA to the livers of laboratory mice using hydrodynamic tail vein injection.

SKU MIR 5240 Category

$222.00

Description

  • Naked Nucleic Acid Delivery– Achieve higher levels of gene expression than compared to polylysine and PEI methods
  • Versatile Platform– for DNA or siRNA delivery using hydrodynamic tail vein injection to the mouse strain of your choice
  • Low Toxicity – Minimized loss of cardiac output compared to saline injections, which allows for quick recovery (within minutes) of the mouse post-injection

 

SKU: MIR 5240

Supporting Data

 

TransIT®-QR Delivery Solution Effectively Delivers the Label IT® Cy®3 RNAi Delivery Control to Hepatocytes. TransIT®-QR Delivery Solution was used to deliver 25 µg of Label IT® Cy®3 RNAi Delivery Control (red) to a mouse using hydrodynamic delivery via the tail vein. Forty-five minutes post-injection the liver was harvested and sections were fixed then counterstained to stain the nuclei (blue) and to stain the actin (green).

 

The TransIT®-QR Solution Minimizes the Loss of Cardiac Output Compared to Injections Performed Using Normal Saline. Mice were anesthetized, connected to an arterial blood pressure monitor, and injected with either TransIT®-QR (Quick Recovery) Delivery Solution (red) or normal saline (blue) using the hydrodynamic tail vein injection procedure. The relative cardiac output was estimated by multiplying the heart rate by the pulse pressure (difference between systolic and diastolic pressures) and scaled to the pre-injection cardiac output.

 

Reporter Gene Knockdown in Multiple Organs After Co-delivery of siRNA and Reporter Plasmids. Mice were injected with 10 µg of plasmid encoding firefly luciferase, 1 µg of plasmid encoding Renilla luciferase, 5 µg of siRNA targeted against firefly luciferase, and 5 µg of control siRNA using the TransIT®-QR Delivery Solution. Twenty-four hours later, the samples were assayed for firefly and Renilla luciferase activity. The level of firefly luciferase expression was normalized to Renilla activity and compared to numbers obtained using the control siRNA. Lewis et al., Nature Genetics 32: 107-8, 2002.

NOTE: Following gene delivery via a tail vein injection, the highest level of transgene expression is found in the liver, with reduced levels of expression found in the spleen, lung, heart and kidneys. siRNA delivery to these organs is not sufficient to achieve appreciable endogenous targeted gene knockdown.

Resources

Specifications

Storage Conditions
All Configurations: Store at 4°C

Product Guarantee
All Configurations: 1 year

Usage Statement
All Configurations: For Research Use Only.

Animal Origin Statement
All Configurations: This product is animal origin free.

 

Technical Product Literature

Full Protocols
TransIT®-QR Delivery Solution Full Transfection Protocol (PDF)

SDS
TransIT®-QR Delivery Solution SDS (PDF)

FAQs

See the In Vivo Delivery FAQs

Using transfection reagents and enhancers from Mirus has given our platform a competitive advantage. Increasing efficiency and lowering costs for all of our porgrams.

 

Sally Mader, PhD
ZYZ Theraputics